vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 27,101 shares, an increase of 62.3% from the December 15th total of 16,694 shares. Based on an average trading volume of 14,747 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.7% of the company’s stock are sold short. Currently, 0.7% of the company’s stock are sold short. Based on an average trading volume of 14,747 shares, the days-to-cover ratio is presently 1.8 days.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on VTVT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Cowen assumed coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating for the company. TD Cowen started coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating and a $67.00 price target for the company. Finally, Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.33.

vTv Therapeutics Trading Down 4.5%

Shares of NASDAQ VTVT opened at $35.59 on Friday. vTv Therapeutics has a twelve month low of $13.46 and a twelve month high of $44.00. The company has a market capitalization of $140.22 million, a price-to-earnings ratio of -10.72 and a beta of 0.48. The business has a 50 day simple moving average of $33.66 and a 200-day simple moving average of $23.92.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Institutional Inflows and Outflows

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP increased its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned about 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent quarter. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.